---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-039083"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:26:46.922422+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius Q2 FY2023 net loss $10.5M ($0.07/share); Halo-Lido Phase 2b topline expected Q2 2023

## Summary
- Net loss of $10.5M ($0.07 per share) for fiscal Q2 ended March 31, 2023, vs $7.6M ($0.05) a year ago.
- Cash $29.1M as of March 31, 2023; raised $15M in May 2023 registered direct offering, extending runway through May 2024.
- Halo-Lido Phase 2b hemorrhoid trial completed; topline results expected by end of calendar Q2 2023.
- Mino-Lok Phase 3 trial at 85 of 92 required events; enrollment ongoing aiming for completion in 2023.
- I/ONTAK BLA under FDA review with PDUFA date July 28, 2023; spinoff preparation continues.

## SEC filing metadata
- accession: 0001213900-23-039083
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/0001213900-23-039083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/ea178475-8k_citiuspharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-039083
- JSON: https://secwatch.observer/filing/0001213900-23-039083.json
- Plain text: https://secwatch.observer/filing/0001213900-23-039083.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported the fiscal second quarter ended March 31, 2023 results: net income Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March, EPS ($0.07) and ($0.10) per share.
  - Period: the fiscal second quarter ended March 31, 2023
  - Net income: Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March
  - EPS: ($0.07) and ($0.10) per share
  - Result: reported results
  source text: r ($0.07) and ($0.10) per share for the three and six months ended March 31, 2023, respectively, compared to a net loss of $7.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/0001213900-23-039083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.